Mary P Pazdur

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Vaccines: an innovative approach to treating cancer
    Mary P Pazdur
    Laboratory of Tumor Immunology and Biology LTIB, National Cancer Institute, Bethesda, Maryland 20892, USA
    J Infus Nurs 30:173-8. 2007
  2. pmc Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer
    James L Gulley
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Cancer Immunol Immunother 59:663-74. 2010
  3. pmc Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma
    James L Gulley
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 14:3060-9. 2008

Detail Information

Publications3

  1. ncbi request reprint Vaccines: an innovative approach to treating cancer
    Mary P Pazdur
    Laboratory of Tumor Immunology and Biology LTIB, National Cancer Institute, Bethesda, Maryland 20892, USA
    J Infus Nurs 30:173-8. 2007
    ..Preventive vaccines that already have been approved will have an impact on the incidence of certain cancers, and research is ongoing into treatment vaccines for various cancers...
  2. pmc Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer
    James L Gulley
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Cancer Immunol Immunother 59:663-74. 2010
    ..This hypothesis-generating study provides evidence that patients with more indolent mCRPC (Halabi predicted survival > or =18 months) may best benefit from vaccine therapy...
  3. pmc Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma
    James L Gulley
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 14:3060-9. 2008
    ..Carcinoembryonic antigen (CEA) and MUC-1 are overexpressed in a substantial proportion of common solid carcinomas. The primary end point of this study was vaccine safety, with immunologic and clinical responses as secondary end points...